Vraylar (cariprazine) 1.5 mg is the starting dose for three FDA-approved conditions: schizophrenia, manic or mixed episodes in bipolar I disorder, and as an add-on to antidepressants for major depressive disorder (MDD). It’s also approved for treating depressive episodes in bipolar I disorder, where the 1.5 mg dose is not just the starting point but has shown direct clinical benefit on its own. You take it once daily, with or without food.
Schizophrenia
For schizophrenia in adults, 1.5 mg is both the starting dose and the lowest dose in the recommended therapeutic range of 1.5 to 6 mg daily. Your prescriber may increase it to 3 mg as early as the second day, then adjust further in 1.5 or 3 mg steps depending on how you respond. Some people stay at 1.5 mg if it controls symptoms adequately, while others need higher doses. The maximum is 6 mg per day.
Bipolar I Disorder: Manic or Mixed Episodes
When prescribed for mania or mixed episodes, 1.5 mg serves strictly as a brief starting dose. The recommended therapeutic range is 3 to 6 mg daily, so your dose will typically be bumped to 3 mg on the second day. In this context, 1.5 mg is a stepping stone rather than a long-term treatment dose.
Bipolar I Depression
This is where the 1.5 mg dose plays a notably different role. Clinical trials found that 1.5 mg per day significantly reduced depressive symptoms in people with bipolar I depression, as measured by a standard depression rating scale. Interestingly, the 3 mg dose did not reach statistical significance for the same outcome in those trials. That makes 1.5 mg a genuinely effective treatment dose for this condition, not just a warm-up to a higher one.
Add-On Treatment for Major Depression
Vraylar was approved as an adjunctive therapy for MDD, meaning it’s added to an antidepressant you’re already taking when that antidepressant alone isn’t enough. The starting dose is 1.5 mg once daily, and unlike the bipolar mania indication, the titration here is slow. Your prescriber shouldn’t increase to 3 mg (the maximum for MDD) until at least Day 15. Clinical trials showed that increasing the dose faster than every 14 days led to more side effects.
How Vraylar Works
Vraylar belongs to a class of medications that regulate dopamine signaling in the brain. It acts as a partial agonist at two types of dopamine receptors, with roughly 10 times more affinity for the D3 receptor than the D2 receptor. In practical terms, “partial agonist” means it dials dopamine activity up or down depending on what’s happening in different brain circuits. In areas where dopamine is overactive (as in psychosis or mania), it dampens the signal. In areas where dopamine may be underactive (as in depression or cognitive symptoms), it provides a mild boost. This dual action helps explain why the same medication can treat conditions as different as mania and depression.
How Long It Stays in Your System
Vraylar has an unusually long presence in the body compared to most psychiatric medications. The drug itself has a half-life of 3 to 9 days, but it breaks down into an active metabolite that continues working with a half-life of 2 to 3 weeks. This metabolite is considered the main contributor to both the drug’s therapeutic effects and its side effects.
After your last dose, it takes roughly one week for blood levels of the total active drug to drop by half, and about 3 to 4 weeks for the longest-lasting metabolite to clear substantially. This means side effects can linger or even appear days after stopping the medication, and benefits may build gradually when you first start taking it.
Common Side Effects at Lower Doses
Restlessness and an inner feeling of needing to move (called akathisia) are among the most commonly reported side effects across Vraylar doses. Other movement-related effects can include stiffness, tremor, or involuntary muscle contractions. These tend to be less frequent at lower doses like 1.5 mg, though they’re still possible given the drug’s long-acting metabolites.
Weight changes are a common concern with psychiatric medications in this class. In a real-world study using electronic health records, about 83% of people taking Vraylar did not experience clinically significant weight gain (defined as gaining 7% or more of their body weight). That makes it relatively favorable compared to some other medications used for the same conditions, though individual responses vary.
Important Safety Information
Vraylar carries an FDA boxed warning stating that medications in this class increase the risk of death in elderly people with dementia-related psychosis. It is not approved for that use. This warning applies to the entire class of atypical antipsychotics, not just Vraylar specifically.
If you take medications that strongly inhibit a specific liver enzyme (CYP3A4), your prescriber may keep you at 1.5 mg or even reduce your dosing frequency to every other day. These drugs slow the breakdown of Vraylar, effectively increasing its concentration in your body. Common examples include certain antifungal and antibiotic medications, so it’s worth making sure your prescriber knows everything you’re taking.